Benjamin Solomon

63.4k total citations · 17 hit papers
415 papers, 20.8k citations indexed

About

Benjamin Solomon is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Benjamin Solomon has authored 415 papers receiving a total of 20.8k indexed citations (citations by other indexed papers that have themselves been cited), including 292 papers in Pulmonary and Respiratory Medicine, 286 papers in Oncology and 77 papers in Cancer Research. Recurrent topics in Benjamin Solomon's work include Lung Cancer Treatments and Mutations (272 papers), Lung Cancer Research Studies (116 papers) and Colorectal Cancer Treatments and Studies (92 papers). Benjamin Solomon is often cited by papers focused on Lung Cancer Treatments and Mutations (272 papers), Lung Cancer Research Studies (116 papers) and Colorectal Cancer Treatments and Studies (92 papers). Benjamin Solomon collaborates with scholars based in Australia, United States and France. Benjamin Solomon's co-authors include Alice T. Shaw, Rebecca S. Heist, Lecia V. Sequist, Enriqueta Felip, Justin F. Gainor, Tony Mok, Keith D. Wilner, Alesha Thai, D. Ross Camidge and A. John Iafrate and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Benjamin Solomon

394 papers receiving 20.5k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

2014 2.3k citations Benjamin Solomon, Yi‐Long Wu et al. profile →
Lung cancer

2021 1.6k citations Benjamin Solomon, Justin F. Gainor et al. profile →
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

2009 1.5k citations Alice T. Shaw, Beow Y. Yeap et al. Journal of Clinical Oncology profile →
Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

2012 976 citations Alice T. Shaw, Mari Mino–Kenudson et al. profile →
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer

2020 649 citations Alice T. Shaw, Filippo de Marinis et al. profile →
Prognostic Significance of p16 ^INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial

2010 571 citations Danny Rischin, Richard J. Young et al. Journal of Clinical Oncology profile →
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

2017 487 citations Alice T. Shaw, Justin F. Gainor et al. profile →
Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non–Small-Cell Lung Cancer and Brain Metastases

2015 468 citations Daniel B. Costa, Alice T. Shaw et al. Journal of Clinical Oncology profile →
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2023 370 citations Benjamin Solomon et al. Annals of Oncology profile →
Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

2019 365 citations Benjamin Solomon, A. John Iafrate et al. Annals of Oncology profile →
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments

2018 336 citations Benjamin Solomon, Richard J. Young et al. profile →
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2023 286 citations Benjamin Solomon et al. Annals of Oncology profile →
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer

2018 285 citations Benjamin Solomon, Yi‐Long Wu et al. Journal of Clinical Oncology profile →
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

2019 269 citations Alice T. Shaw, Benjamin Solomon et al. Journal of Clinical Oncology profile →
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

2022 129 citations Benjamin Solomon, Filippo de Marinis et al. profile →
Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

2022 119 citations Alexander Drilon, Vivek Subbiah et al. Journal of Clinical Oncology profile →
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

2024 118 citations Benjamin Solomon, Alice T. Shaw et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Benjamin Solomon

Since Specialization

Citations

This map shows the geographic impact of Benjamin Solomon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Solomon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Solomon more than expected).

Fields of papers citing papers by Benjamin Solomon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Solomon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Solomon. The network helps show where Benjamin Solomon may publish in the future.

Co-authorship network of co-authors of Benjamin Solomon

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin Solomon. A scholar is included among the top collaborators of Benjamin Solomon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin Solomon. Benjamin Solomon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Adverse drug reactions and contributing factors in patients with drug-resistant tuberculosis: A 7-year retrospective cohort study in Addis Ababa, Ethiopia 2025 ·Journal of Clinical Tuberculosis and Other Mycobacterial Diseases ·Benjamin Solomon, Yimtubezinash Woldeamanuel, (unknown), Mbazi Senkoro, Tsegahun Manyazewal	0
2	Completion of Pembrolizumab in Advanced Non-Small Cell Lung Cancer—Real World Outcomes After Two Years of Therapy (COPILOT) 2024 ·Clinical Lung Cancer ·A Fantoni, Lydia Warburton, Benjamin Solomon, Marliese Alexander, (unknown), Lauren Brown, Inês Pires da Silva, Adnan Nagrial, (unknown), Malinda Itchins, Nick Pavlakis, Samantha Bowyer	0
3	OA13.04 ALINA Safety Results: Adjuvant Alectinib vs Chemotherapy in Patients with Resected ALK+ Non-Small Cell Lung Cancer (NSCLC) 2024 ·Journal of Thoracic Oncology ·Hidehito Horinouchi, Benjamin Solomon, Yi‐Long Wu, (unknown), Matomo Nishio, Jin Seok Ahn, D.H. Lee, J.-S. Lee, Wen‐Zhao Zhong, Maximilian J. Hochmair, Igor Bondarenko, (unknown), Achim Rittmeyer, Beiying Ding, Thorsten Ruf, (unknown), Astrid Scalori, Rafał Dziadziuszko	1
4	1206MO ALINA: Exploratory biomarker analyses in patients (pts) with resected ALK+ non-small cell lung cancer (NSCLC) treated with adjuvant alectinib vs chemotherapy (chemo) 2024 ·Annals of Oncology ·Benjamin Solomon, Yi‐Long Wu, Rafał Dziadziuszko, Fabrice Barlési, Makoto Nishio, (unknown), Hidehito Horinouchi, Maximilian J. Hochmair, Filippo de Marinis, M.R. Migliorino, (unknown), Hakan Harputluoğlu, (unknown), Krittiya Korphaisarn, (unknown), T Lohmann, (unknown), V.R. Archer, Małgorzata Nowicka, Johannes Noé	1
5	Trends in primary care blood tests prior to lung and colorectal cancer diagnosis—A retrospective cohort study using linked Australian data 2024 ·Cancer Medicine ·Meena Rafiq, Allison Drosdowsky, Benjamin Solomon, Marliese Alexander, Peter Gibbs, Gavin Wright, Justin Yeung, Georgios Lyratzopoulos, (unknown)	2
6	CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial 2024 ·Investigational New Drugs ·Andrew J. Armstrong, Ravit Geva, Hyun Cheol Chung, Charlotte Lemech, Wilson H. Miller, Aaron R. Hansen, Jong Seok Lee, Frank Tsai, Benjamin Solomon, Tae Min Kim, Christian Rolfo, Vincent L. Giranda, Yixin Ren, Fang Liu, (unknown), Tomoko Freshwater, Judy S. Wang	33
7	A Phase 1b/2 Study of Alpelisib in Combination with Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma 2023 ·Targeted Oncology ·Albiruni Ryan Abdul Razak, Hung‐Ming Wang, Jang‐Yang Chang, Myung‐Ju Ahn, Pamela N. Münster, George R. Blumenschein, Benjamin Solomon, Wan‐Teck Lim, Ruey‐Long Hong, David G. Pfister, Nabil F. Saba, Se‐Hoon Lee, Carla van Herpen, Cornelia Quadt, Douglas Bootle, Lars Blumenstein, David Demanse, Jean‐Pierre Delord	10
8	538P First-line chemoimmunotherapy for metastatic thymic carcinoma 2023 ·Annals of Oncology ·(unknown), Michael J. Alexander, (unknown), Michael Faltys, (unknown), Lydia Warburton, A Fantoni, Timothy Clay, Phillip Antippa, Benjamin Solomon, Thomas John	0
9	MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors 2023 ·Journal of Thoracic Oncology ·Marcelo V. Negrão, Philippe A. Cassier, Benjamin Solomon, Martin Schüler, (unknown), Sara Cresta, Christophe Dooms, Daniel Shao-Weng Tan, Herbert H. Loong, Alessio Amatu, (unknown), Lauren Fairchild, Laurent Sansregret, (unknown), Anna F. Farago, Byoung Chul Cho	16
10	2229P Updated safety and efficacy of selpercatinib in patients (pts) with RET-activated thyroid cancer: Data from LIBRETTO-001 2023 ·Annals of Oncology ·Lori J. Wirth, Vivek Subbiah, Francis P. Worden, Benjamin Solomon, Bruce Robinson, Julien Hadoux, (unknown), (unknown), Barbara Deschler-Baier, (unknown), (unknown), (unknown), Patricia Maeda, Alexander Drilon, Philippe A. Cassier	3
11	An inverse stage‐shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID‐19 pandemic 2021 ·Asia-Pacific Journal of Clinical Oncology ·Koen Degeling, Nancy N. Baxter, Jon Emery, Mark A. Jenkins, Fanny Franchini, Peter Gibbs, G. Bruce Mann, Grant A. McArthur, Benjamin Solomon, Maarten J. IJzerman	56
12	Prognostic Significance of PD-L1+ and CD8+ Immune Cells in HPV+ Oropharyngeal Squamous Cell Carcinoma 2018 ·Cancer Immunology Research ·Benjamin Solomon, Richard J. Young, Mathias Bressel, Damien Urban, Shona Hendry, Alesha A. Thai, Christopher Angel, (unknown), Marcin Kowanetz, Tsien Fua, June Corry, Stephen B. Fox, Danny Rischin	100
13	Cisplatin Increases Sensitivity to FGFR Inhibition in Patient-Derived Xenograft Models of Lung Squamous Cell Carcinoma 2017 ·Molecular Cancer Therapeutics ·Clare E. Weeden, Aliaksei Z. Holik, Richard J. Young, Stephen Ma, (unknown), Stephen B. Fox, Phillip Antippa, Louis Irving, Daniel Steinfort, Gavin Wright, Prudence A. Russell, Matthew E. Ritchie, Christopher J. Burns, Benjamin Solomon, Marie-Liesse Asselin-Labat	19
14	Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib 2015 ·Clinical Cancer Research ·Justin F. Gainor, Daniel Shao-Weng Tan, (unknown), Benjamin Solomon, (unknown), Chiara Lazzari, Filippo de Marinis, Gianluca Spitaleri, Katherine R. Schultz, Luc Friboulet, Beow Y. Yeap, Jeffrey A. Engelman, Alice T. Shaw	135
15	Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs 2015 ·Cancer Research ·Francis W. Hunter, Richard J. Young, Zvi Shalev, Ravi N. Vellanki, Jingli Wang, Yongchuan Gu, (unknown), (unknown), Ilan Weinreb, David P. Goldstein, Jason Moffat, Troy Ketela, Kevin R. Brown, Marianne Koritzinsky, Benjamin Solomon, Danny Rischin, William R. Wilson, Bradly G. Wouters	59
16	Relationship between Epidermal Growth Factor Receptor Status, p16INK4A, and Outcome in Head and Neck Squamous Cell Carcinoma 2011 ·Cancer Epidemiology Biomarkers & Prevention ·Richard J. Young, Danny Rischin, Richard Fisher, Grant A. McArthur, Stephen B. Fox, Lester J. Peters, June Corry, Annette M. Lim, Kelly Waldeck, Benjamin Solomon	70
17	Changes in 18F-Fluorodeoxyglucose and 18F-Fluorodeoxythymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer Treated with Erlotinib 2011 ·Clinical Cancer Research ·Linda Mileshkin, Rodney J. Hicks, Brett Hughes, Paul Mitchell, Veena Charu, Barbara J. Gitlitz, David Macfarlane, Benjamin Solomon, Lukas C. Amler, Wei Yu, Andrea Pirzkall, Bernard M. Fine	106
18	Inhibition of DNA-Dependent Protein Kinase Induces Accelerated Senescence in Irradiated Human Cancer Cells 2011 ·Molecular Cancer Research ·Arun Azad, Susan Jackson, Carleen Cullinane, Anthony Natoli, Paul M. Neilsen, David F. Callen, Sauveur-Michel Maira, Wolfgang Hackl, Grant A. McArthur, Benjamin Solomon	51
19	Prognostic Significance of p16 ^INK4A and Human Papillomavirus in Patients With Oropharyngeal Cancer Treated on TROG 02.02 Phase III Trial breakdown → 2010 ·Journal of Clinical Oncology ·Danny Rischin, Richard J. Young, Richard Fisher, Stephen B. Fox, Quynh‐Thu Le, Lester J. Peters, Benjamin Solomon, Jimin Choi, Brian O’Sullivan, Liz Kenny, Grant A. McArthur	571
20	Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK breakdown → 2009 ·Journal of Clinical Oncology ·Alice T. Shaw, Beow Y. Yeap, Mari Mino–Kenudson, Subba R. Digumarthy, Daniel B. Costa, Rebecca S. Heist, Benjamin Solomon, Hannah Stubbs, Sonal Admane, Ultan McDermott, Jeffrey Settleman, Susumu Kobayashi, Eugene J. Mark, Scott J. Rodig, Lucian R. Chirieac, Eunice L. Kwak, Thomas J. Lynch, A. John Iafrate	1463

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact